JP2025506318A5 - - Google Patents

Info

Publication number
JP2025506318A5
JP2025506318A5 JP2023547446A JP2023547446A JP2025506318A5 JP 2025506318 A5 JP2025506318 A5 JP 2025506318A5 JP 2023547446 A JP2023547446 A JP 2023547446A JP 2023547446 A JP2023547446 A JP 2023547446A JP 2025506318 A5 JP2025506318 A5 JP 2025506318A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506318A (ja
Filing date
Publication date
Priority claimed from CN202210132762.1A external-priority patent/CN114181310B/zh
Application filed filed Critical
Publication of JP2025506318A publication Critical patent/JP2025506318A/ja
Publication of JP2025506318A5 publication Critical patent/JP2025506318A5/ja
Pending legal-status Critical Current

Links

JP2023547446A 2022-02-14 2023-02-14 抗tigit抗体と抗pd-1-抗vegfa二重特異性抗体を含有する医薬組成物及び使用 Pending JP2025506318A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210132762.1 2022-02-14
CN202210132762.1A CN114181310B (zh) 2022-02-14 2022-02-14 抗tigit抗体、其药物组合物及用途
PCT/CN2023/075862 WO2023151693A1 (zh) 2022-02-14 2023-02-14 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途

Publications (2)

Publication Number Publication Date
JP2025506318A JP2025506318A (ja) 2025-03-11
JP2025506318A5 true JP2025506318A5 (cg-RX-API-DMAC7.html) 2026-02-27

Family

ID=80607015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547446A Pending JP2025506318A (ja) 2022-02-14 2023-02-14 抗tigit抗体と抗pd-1-抗vegfa二重特異性抗体を含有する医薬組成物及び使用

Country Status (10)

Country Link
US (1) US20250034253A1 (cg-RX-API-DMAC7.html)
EP (1) EP4273170A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506318A (cg-RX-API-DMAC7.html)
KR (1) KR20240145470A (cg-RX-API-DMAC7.html)
CN (1) CN114181310B (cg-RX-API-DMAC7.html)
AU (1) AU2023217806A1 (cg-RX-API-DMAC7.html)
CA (1) CA3208430A1 (cg-RX-API-DMAC7.html)
IL (1) IL314785A (cg-RX-API-DMAC7.html)
MX (1) MX2024009976A (cg-RX-API-DMAC7.html)
WO (1) WO2023151693A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
US20240352153A1 (en) * 2021-07-23 2024-10-24 Akeso Biopharma, Inc Pharmaceutical composition and use
KR20240046905A (ko) * 2021-08-20 2024-04-11 아케소 바이오파마, 인크. 항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도
CN114181310B (zh) * 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途
CN117003883A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合tigit和vegf的双特异性分子及其用途
CN116284395B (zh) * 2022-12-12 2024-11-08 合肥天港免疫药物有限公司 抗cd155的抗体及其应用
KR20250112917A (ko) * 2022-12-12 2025-07-24 라노바 메디신즈 리미티드 Pd1 및 vegf를 표적으로 하는 이중특이적 항체
CN116143923B (zh) * 2022-12-30 2025-11-11 合肥天港免疫药物有限公司 高亲和力tigit抗体及其应用
IL322840A (en) * 2023-02-20 2025-10-01 Akeso Biopharma Co Ltd Fusion protein comprising a TGF-βRII extracellular region fragment, its pharmaceutical composition and use
KR20260074706A (ko) * 2023-09-14 2026-05-26 아케소 바이오파마 컴퍼니 리미티드 약물 조합 및 그 용도
WO2025140188A1 (zh) * 2023-12-29 2025-07-03 成都优洛生物科技有限公司 抗tl1a抗体或其抗原结合片段及应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
DK1907000T4 (da) * 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
CA2957722C (en) * 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
SG10202007764TA (en) 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
LT3618863T (lt) * 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
CN111051347B (zh) * 2017-09-29 2021-12-21 江苏恒瑞医药股份有限公司 Tigit抗体、其抗原结合片段及医药用途
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
MX2022006330A (es) * 2019-11-25 2022-08-17 Akeso Biopharma Inc Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo.
CN110960543A (zh) * 2019-12-10 2020-04-07 安徽瀚海博兴生物技术有限公司 一种联合抗vegf-抗pd1双特异性抗体用于制备抗癌药物
TWI813934B (zh) * 2020-01-21 2023-09-01 大陸商甫康(上海)健康科技有限責任公司 一種雙特異性抗pd-l1/vegf抗體及其用途
IL294800A (en) * 2020-01-27 2022-09-01 Genentech Inc Methods of treating cancer with an antibody to an anti-ti antagonist
WO2021263085A2 (en) * 2020-06-25 2021-12-30 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
CA3189730A1 (en) * 2020-08-05 2022-02-10 Crystal Bioscience Inc. Anti-tigit antibody and methods of use thereof
US11028172B1 (en) * 2020-11-10 2021-06-08 Lepu Biopharma Co., Ltd. Anti-TIGIT antibodies and uses thereof
CN114181310B (zh) * 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途

Similar Documents

Publication Publication Date Title
US11155615B2 (en) Anti-ROR1 antibodies
JP2024509018A5 (cg-RX-API-DMAC7.html)
RU2016147206A (ru) Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
JP2008531576A5 (cg-RX-API-DMAC7.html)
JP2024520666A5 (cg-RX-API-DMAC7.html)
JP2025520232A5 (cg-RX-API-DMAC7.html)
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
CN115197325A (zh) 抗体在抗肿瘤治疗中的用途
JP2024515618A5 (cg-RX-API-DMAC7.html)
US20250270323A1 (en) Hhla2 binding agents with novel activity
Guo et al. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer
US11648310B2 (en) Combination of anti-FGFR4-antibody and bile acid sequestrant
JP2024536383A5 (cg-RX-API-DMAC7.html)
CN101175495B (zh) 抗癌化合物的组合
JP7840569B2 (ja) ヒト4-1bbアゴニスト抗体およびその使用方法
CN103768596B (zh) 用于肿瘤治疗的组合产品、其用途及相关方法
TWI814752B (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
JPWO2022019259A5 (cg-RX-API-DMAC7.html)
TW202214287A (zh) TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途
CA3304458A1 (en) Pharmaceutical combination and use
RU2025127006A (ru) Анти-lag3 антитело, фармацевтическая композиция и применение
CN112543637B (zh) 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途
HK40080887A (en) Use of antibody in anti-tumor treatment
CN120957726A (zh) 抗体-药物偶联物与癌症疗法的组合及其用途
RU2025130923A (ru) Медицинское применение анти-ctla4 и анти-pd-1 биспецифического антитела